{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-155503","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2025-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.600079+00:00","generated_at":"2026-05-18T09:27:44.686166+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"UroGen awards special bonuses totaling $845K to CEO, CFO, GC for ZUSDURI FDA approval","bullets":["CEO Elizabeth Barrett receives $645,000; CFO Chris Degnan and GC Jason Smith each get $100,000.","Bonuses approved June 30, 2025, for leadership leading to FDA approval of ZUSDURI for recurrent low-grade intermediate risk NMIBC.","ZUSDURI is a novel therapy for non-muscle invasive bladder cancer (NMIBC).","One-time special awards; no recurrence or changes to base compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-155503","json":"https://secwatch.observer/filing/0001193125-25-155503.json","markdown":"https://secwatch.observer/filing/0001193125-25-155503.md","text":"https://secwatch.observer/filing/0001193125-25-155503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312525155503/0001193125-25-155503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312525155503/d941822d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:27:44.686166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}